PL2718316T3 - Polipeptydy - Google Patents

Polipeptydy

Info

Publication number
PL2718316T3
PL2718316T3 PL12729418T PL12729418T PL2718316T3 PL 2718316 T3 PL2718316 T3 PL 2718316T3 PL 12729418 T PL12729418 T PL 12729418T PL 12729418 T PL12729418 T PL 12729418T PL 2718316 T3 PL2718316 T3 PL 2718316T3
Authority
PL
Poland
Prior art keywords
polypeptides
Prior art date
Application number
PL12729418T
Other languages
English (en)
Inventor
Lauge SCHÄFFER
Thomas Kruse
Henning THØGERSEN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL2718316T3 publication Critical patent/PL2718316T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57527Calcitonin gene related peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
PL12729418T 2011-06-10 2012-06-08 Polipeptydy PL2718316T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11169405 2011-06-10
US201161496113P 2011-06-13 2011-06-13
EP12729418.9A EP2718316B1 (en) 2011-06-10 2012-06-08 Polypeptides
PCT/EP2012/060900 WO2012168432A1 (en) 2011-06-10 2012-06-08 Polypeptides

Publications (1)

Publication Number Publication Date
PL2718316T3 true PL2718316T3 (pl) 2020-06-29

Family

ID=47295518

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12729418T PL2718316T3 (pl) 2011-06-10 2012-06-08 Polipeptydy

Country Status (18)

Country Link
US (4) US8722849B2 (pl)
EP (3) EP2718316B1 (pl)
JP (3) JP6121992B2 (pl)
KR (1) KR102066987B1 (pl)
CN (3) CN103596973A (pl)
AU (1) AU2012266269B2 (pl)
BR (1) BR112013031268B1 (pl)
CA (1) CA2838884C (pl)
ES (1) ES2664509T3 (pl)
IL (1) IL229258B (pl)
MX (1) MX341324B (pl)
MY (1) MY161773A (pl)
PL (1) PL2718316T3 (pl)
RS (1) RS59977B1 (pl)
RU (1) RU2669999C2 (pl)
SI (1) SI2718316T1 (pl)
WO (3) WO2012168430A2 (pl)
ZA (1) ZA201309174B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드
ES2640285T3 (es) * 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
AR096440A1 (es) 2013-05-28 2015-12-30 Takeda Pharmaceuticals Co Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
WO2016034604A1 (en) * 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
CA2971721A1 (en) 2014-12-23 2016-06-30 Colgate-Palmolive Company Oral care composition
CN105985995A (zh) * 2015-01-29 2016-10-05 暨南大学 一种利用家蚕生物反应器生产普兰林肽(pa)的方法
EA035791B1 (ru) * 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
CN106554405B (zh) * 2015-09-30 2020-04-24 深圳翰宇药业股份有限公司 一种多肽及其用途、制备方法
CN106928086B (zh) 2015-12-31 2019-05-31 深圳翰宇药业股份有限公司 一种长链化合物的制备方法
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
KR102911883B1 (ko) 2018-10-11 2026-01-13 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
CN113614101B (zh) 2019-02-22 2024-07-16 洛约拉马利蒙特大学 淀粉样肽的变体
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
IL300620B2 (en) 2020-09-24 2025-12-01 Gubra As Ham15-52 analogues with improved amylin receptor (hamy3r) potency
TWI850611B (zh) 2020-12-18 2024-08-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
TWI876242B (zh) 2021-12-13 2025-03-11 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
CN118973602A (zh) 2022-03-30 2024-11-15 诺和诺德股份有限公司 配制方法
EP4534553A1 (en) * 2022-05-27 2025-04-09 Hangzhou Sciwind Biosciences Co., Ltd. Human amylin analog, and derivative and use thereof
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.
IL319599A (en) 2022-09-19 2025-05-01 Zealand Pharma As Combination therapy
KR20250127104A (ko) * 2022-12-22 2025-08-26 노보 노르디스크 에이/에스 아밀린 수용체 작용제
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
WO2024164776A1 (zh) * 2023-02-10 2024-08-15 杭州先为达生物科技股份有限公司 多肽及其衍生物、组合物及其应用
TW202500183A (zh) 2023-06-15 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
TW202504913A (zh) 2023-06-21 2025-02-01 丹麥商西蘭製藥公司 減重
EP4731239A1 (en) 2023-06-21 2026-04-29 Zealand Pharma A/S Analogues with improved properties
KR20260032481A (ko) 2023-06-30 2026-03-09 질랜드 파마 에이/에스 병용 요법
WO2025114501A1 (en) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonists of the glp-1, gip, and amylin receptors
WO2025160082A1 (en) * 2024-01-23 2025-07-31 Viking Therapeutics, Inc. Amylin analogs
TW202545982A (zh) * 2024-02-07 2025-12-01 大陸商江蘇恆瑞醫藥股份有限公司 胰島澱粉樣多肽類似物及其醫藥用途
WO2025172606A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721760A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603079A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4603080A1 (en) 2024-02-16 2025-08-20 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684802A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
WO2025172605A1 (en) 2024-02-16 2025-08-21 Adocia Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4684801A1 (en) 2024-07-23 2026-01-28 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP4721761A1 (en) 2024-10-07 2026-04-08 Adocia Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP1053001B1 (en) 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
WO1999057147A1 (fr) * 1998-04-30 1999-11-11 Kirin Brewery Company, Limited Mutants de la thrombopoietine humaine
AU4930299A (en) * 1998-07-31 2000-02-21 Kirin Beer Kabushiki Kaisha Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005097825A2 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー/エス アミリン誘導体
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CN102076353A (zh) 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
EP2504355B1 (en) 2009-11-25 2015-07-22 Novo Nordisk A/S Method for making polypeptides
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드

Also Published As

Publication number Publication date
ZA201309174B (en) 2022-08-31
CA2838884C (en) 2022-11-29
CN103596972A (zh) 2014-02-19
KR102066987B1 (ko) 2020-01-16
EP2718316B1 (en) 2019-12-04
EP2718315B1 (en) 2017-12-27
RS59977B1 (sr) 2020-03-31
US9029325B2 (en) 2015-05-12
RU2013156937A (ru) 2015-07-20
US20130059770A1 (en) 2013-03-07
WO2012168431A3 (en) 2013-01-31
JP2014519510A (ja) 2014-08-14
JP6121992B2 (ja) 2017-04-26
EP2718316A1 (en) 2014-04-16
EP2718314A2 (en) 2014-04-16
RU2669999C2 (ru) 2018-10-17
US8575090B2 (en) 2013-11-05
MX2013013913A (es) 2013-12-16
BR112013031268B1 (pt) 2020-05-12
WO2012168430A3 (en) 2013-01-31
BR112013031268A8 (pt) 2018-01-16
KR20140043764A (ko) 2014-04-10
CN103596972B (zh) 2018-03-20
US20140018286A1 (en) 2014-01-16
CA2838884A1 (en) 2012-12-13
MX341324B (es) 2016-08-16
AU2012266269B2 (en) 2017-04-06
JP2014519511A (ja) 2014-08-14
AU2012266269A1 (en) 2013-11-21
EP2718315A2 (en) 2014-04-16
IL229258B (en) 2019-11-28
ES2664509T3 (es) 2018-04-19
WO2012168432A1 (en) 2012-12-13
US20130005646A1 (en) 2013-01-03
CN103649115B (zh) 2016-01-20
CN103649115A (zh) 2014-03-19
US8722849B2 (en) 2014-05-13
US20130012427A1 (en) 2013-01-10
WO2012168430A2 (en) 2012-12-13
IL229258A0 (en) 2014-01-30
SI2718316T1 (sl) 2020-03-31
CN103596973A (zh) 2014-02-19
JP6247205B2 (ja) 2017-12-13
US8741836B2 (en) 2014-06-03
JP2014519509A (ja) 2014-08-14
MY161773A (en) 2017-05-15
BR112013031268A2 (pt) 2016-11-22
WO2012168431A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
IL291571A (en) cx3cr1 binding polypeptides
ZA201309174B (en) Polypeptides
DK3505720T3 (en) Cementering under styret tryk
ZA201300994B (en) Polypeptides
GB201220474D0 (en) Polypeptides
AP2014007621A0 (en) 2-Thiopyrimidinones
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
LT2699681T (lt) Hipoalergenas
PT2776382T (pt) Folatos de 18f-sacárido
PL2745011T3 (pl) Zespół motopompy
GB2491829B (en) J-cup
GB201210292D0 (en) Hydraulischer antrieb
HUE047406T2 (hu) Polipeptidek
AU5026P (en) Goldstrike Agapanthus inapertus
AU5031P (en) BESYS Beschorneria yuccoides
AU4540P (en) BUNNAN Baloskion tetraphyllum
GB201112849D0 (en) Polypeptide
GB201112985D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
GB201115014D0 (en) Peptides
GB201103961D0 (en) Binding polypeptides
GB201103968D0 (en) Detecting polypeptides
AP00723S1 (en) Autorickshaw
GB201118263D0 (en) Corcost-CH001